{"id":595,"date":"2024-03-11T05:29:19","date_gmt":"2024-03-11T05:29:19","guid":{"rendered":"http:\/\/www.wallstreetendeavor.loc\/?p=595"},"modified":"2024-05-13T15:19:50","modified_gmt":"2024-05-13T15:19:50","slug":"innate-pharma-leadership-change","status":"publish","type":"post","link":"https:\/\/wallstreetendeavor.com\/de\/pharmaceutical\/innate-pharma-leadership-change\/","title":{"rendered":"Innate Pharma Leadership Change"},"content":{"rendered":"<p>Innate Pharma, a global clinical-stage biotechnology company, announced a major leadership transition. Mondher Mahjoubi, the Chief Executive Officer (CEO), has resigned to pursue an opportunity at a large pharmaceutical company. Starting January 2024, Herv\u00e9 Brailly, the current Chairman of the Supervisory Board, former CEO, and co-founder of Innate Pharma, will take over as interim CEO. The company, known for developing immunotherapies for cancer patients, has made strides under Mahjoubi&#8217;s leadership, including strengthening pharmaceutical alliances and advancing clinical pipelines<\/p>","protected":false},"excerpt":{"rendered":"<p>Innate Pharma, a global clinical-stage biotechnology company, announced a major leadership transition. Mondher Mahjoubi, the Chief Executive Officer (CEO), has resigned to pursue an opportunity at a large pharmaceutical company. Starting January 2024, Herv\u00e9 Brailly, the current Chairman of the Supervisory Board, former CEO, and co-founder of Innate Pharma, will take over as interim CEO. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1217,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7],"tags":[30],"class_list":["post-595","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical","tag-technology"],"acf":{"featured_video_oembed":"","featured_post_summary":"","post_source":""},"_links":{"self":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/comments?post=595"}],"version-history":[{"count":1,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/595\/revisions"}],"predecessor-version":[{"id":596,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/posts\/595\/revisions\/596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media\/1217"}],"wp:attachment":[{"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/media?parent=595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/categories?post=595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wallstreetendeavor.com\/de\/wp-json\/wp\/v2\/tags?post=595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}